These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 35711024)

  • 1. Psilocybin for Trauma-Related Disorders.
    Khan AJ; Bradley E; O'Donovan A; Woolley J
    Curr Top Behav Neurosci; 2022; 56():319-332. PubMed ID: 35711024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of potential psychedelic treatments for PTSD.
    Henner RL; Keshavan MS; Hill KP
    J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reviewing the Potential of Psychedelics for the Treatment of PTSD.
    Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E
    Int J Neuropsychopharmacol; 2020 Jun; 23(6):385-400. PubMed ID: 32170326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psychedelics in the treatment of PTSD].
    Vermetten E; Krediet E; Bostoen T; Breeksema JJ; Schoevers RA; van den Brink W
    Tijdschr Psychiatr; 2020; 62(8):640-649. PubMed ID: 32816292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.
    Raut SB; Marathe PA; van Eijk L; Eri R; Ravindran M; Benedek DM; Ursano RJ; Canales JJ; Johnson LR
    Pharmacol Ther; 2022 Nov; 239():108195. PubMed ID: 35489438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin and MDMA for the treatment of trauma-related psychopathology.
    Bird CIV; Modlin NL; Rucker JJH
    Int Rev Psychiatry; 2021 May; 33(3):229-249. PubMed ID: 34121583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine.
    Averill LA; Abdallah CG
    Expert Opin Investig Drugs; 2022 Feb; 31(2):133-137. PubMed ID: 35188023
    [No Abstract]   [Full Text] [Related]  

  • 12. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
    Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need for establishing best practices and gold standards in psychedelic medicine.
    Feduccia A; Agin-Liebes G; Price CM; Grinsell N; Paradise S; Rabin DM
    J Affect Disord; 2023 Jul; 332():47-54. PubMed ID: 37003433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 17. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD.
    Davis AK; Levin AW; Nagib PB; Armstrong SB; Lancelotta RL
    BMJ Open; 2023 May; 13(5):e068884. PubMed ID: 37142308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.
    Varker T; Watson L; Gibson K; Forbes D; O'Donnell ML
    J Psychoactive Drugs; 2021; 53(1):85-95. PubMed ID: 32931403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.